| Outcome Measures: |
Primary: Change in urine albumin creatine ratio (ACR)., First morning urine (10-15ml) of the subject is collected with a clean urine collection tube (or vial)., Baseline and 1,2,3,6 months. | Secondary: The incidence of ≧30% decline in eGFR from baseline., Monitoring changes in glomerular functions measured in estimated glomerular filtration rate (eGFR) \[CKD-EPI creatinine-cystatin equation (2012)\]., half a year|Change in urine α1-microglobulin., Baseline and 1,2,3,6 months.|Change in urine β2-microglobulin., Baseline and 1,2,3,6 months.|Change in urine N-acetyl-β-D-glucosidase., Baseline and 1,2,3,6 months.|Change in urine neutrophil gelatinase-associated lipocalin., Baseline and 1,2,3,6 months.|Change in inflammation level., Change in hs-CRP level., Baseline and 1,2,3,6 months.|Change in HbA1c., Baseline and 1,3,6 months.|Change in blood pressure control., Baseline and 1,2,3,6 months.|Change in blood lipids., Baseline and 1,3,6 months.|Life quality evaluation, Change in SF-36 Scale score., Baseline and 6 months.|Incidence of Treatment-Emergent Adverse Events, Treatment-related adverse events as assessed by deterioration of liver functions with other reasons excluded, self-report of gastrointestinal symptoms associated with drug intake, etc., half a year
|
